Literature DB >> 17021642

The treatment of hormone-refractory prostate cancer: docetaxel and beyond.

Daniel P Petrylak.   

Abstract

Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer.

Entities:  

Year:  2006        PMID： 17021642      PMCID： PMC1578715     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  14 in total

1.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

Authors:  D J George; S Halabi; T F Shepard; N J Vogelzang; D F Hayes; E J Small; P W Kantoff
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Authors:  W D Figg; W Dahut; P Duray; M Hamilton; A Tompkins; S M Steinberg; E Jones; A Premkumar; W M Linehan; M K Floeter; C C Chen; S Dixon; D R Kohler; E A Krüger; E Gubish; J M Pluda; E Reed
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

3.  Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.

Authors:  Y R Wang; D P Wigington; S A Strugnell; J C Knutson
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

4.  Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

Authors:  Garth Beinart; Brian I Rini; Vivian Weinberg; Eric J Small
Journal:  Clin Prostate Cancer       Date:  2005-06

5.  Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

Authors:  T M Beer; K M Hough; M Garzotto; B A Lowe; W D Henner
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

6.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

7.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.

Authors:  R H Getzenberg; B W Light; P E Lapco; B R Konety; A K Nangia; J S Acierno; R Dhir; Z Shurin; R S Day; D L Trump; C S Johnson
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

Review 8.  The endothelin axis: emerging role in cancer.

Authors:  Joel Nelson; Anna Bagnato; Bruno Battistini; Perry Nisen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

Review 9.  Chemotherapy for androgen-independent prostate cancer.

Authors:  Daniel P Petrylak
Journal:  Semin Urol Oncol       Date:  2002-08

10.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Authors:  Howard L Kaufman; Wei Wang; Judith Manola; Robert S DiPaola; Yoo-Joung Ko; Christopher Sweeney; Theresa L Whiteside; Jeffrey Schlom; George Wilding; Louis M Weiner
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  13 in total

1.  Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.

Authors:  Mi Zhang; Mary Osisami; Jinlu Dai; Jill M Keller; June Escara-Wilke; Atsushi Mizokami; Evan T Keller
Journal:  Mol Cancer Res       Date:  2017-01-13       Impact factor: 5.852

2.  Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.

Authors:  Mohamed O Abdalla; Prasanthi Karna; Hari Krishna Sajja; Hui Mao; Clayton Yates; Timothy Turner; Ritu Aneja
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

3.  Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Authors:  Yuan-Yuan Qu; Bo Dai; Yun-Yi Kong; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Chun-Guang Ma; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2012-11-12       Impact factor: 3.285

4.  Synergistic antimicrotubule therapy for prostate cancer.

Authors:  Vaishali Pannu; Prasanthi Karna; Hari Krishna Sajja; Deep Shukla; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2010-11-16       Impact factor: 5.858

5.  NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.

Authors:  Ricardo Parrondo; Alicia de las Pozas; Teresita Reiner; Priyamvada Rai; Carlos Perez-Stable
Journal:  Mol Cancer       Date:  2010-07-09       Impact factor: 27.401

Review 6.  [The hormone refractory prostate cancer - a challenge for the internal specialist].

Authors:  Stefan Kudlacek; Johannes G Meran; Dora Beke
Journal:  Wien Med Wochenschr       Date:  2007

7.  27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells.

Authors:  Shaneabbas Raza; Megan Meyer; Jared Schommer; Kimberly D P Hammer; Bin Guo; Othman Ghribi
Journal:  Med Oncol       Date:  2016-01-05       Impact factor: 3.064

8.  WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth.

Authors:  Liangyou Wang; Daniel T Sloper; Sadiya N Addo; Defeng Tian; Joel W Slaton; Chengguo Xing
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Authors:  Ankur Sharma; Clay E S Comstock; Erik S Knudsen; Khanh H Cao; Janet K Hess-Wilson; Lisa M Morey; Jason Barrera; Karen E Knudsen
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies.

Authors:  Vanna Sanna; Anna Maria Roggio; Anna Maria Posadino; Annalisa Cossu; Salvatore Marceddu; Alberto Mariani; Valeria Alzari; Sergio Uzzau; Gianfranco Pintus; Mario Sechi
Journal:  Nanoscale Res Lett       Date:  2011-03-28       Impact factor: 4.703
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.